Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (NASDAQ:JAGX) announced the approval of all four proposals at its 2022 Annual Meeting of Stockholders held on June 10, 2022. The details of the proposals are available in the definitive proxy statement filed with the SEC. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues, including Mytesi^®, which is specifically for noninfectious diarrhea in HIV/AIDS patients. The company aims to expand access to its products in Europe through its subsidiary Napo Therapeutics.

Jaguar Health (NASDAQ:JAGX) announced its participation in BIO 2022, scheduled for June 13-16, 2022, in San Diego. Karen Brunke, PhD, EVP of Corporate Development, will engage in one-on-one meetings to seek partnerships related to crofelemer, an FDA-approved treatment for diarrhea in adults with HIV/AIDS. The company aims to explore further applications for cancer therapy-related diarrhea and inflammatory bowel disease. Additionally, Jaguar is pursuing collaborations to advance its extensive library of medicinal plants and recently collaborated with Filament Health for developing botanical prescription drugs.

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Therapeutics, has submitted an Orphan Drug Designation application for crofelemer to the European Medicines Agency (EMA) for microvillus inclusion disease (MVID), a severe congenital diarrheal disorder. This submission marks a significant step towards addressing the unmet medical need for MVID, which can cause severe complications in newborns and children. If granted, the designation offers regulatory benefits, including a 10-year market exclusivity upon approval.

Jaguar Health (NASDAQ:JAGX) presented a study on crofelemer as a potential treatment for Microvillus Inclusion Disease (MVID), a severe congenital diarrheal disorder, at Digestive Disease Week 2022. The study, led by Dr. Jay Thiagarajah, demonstrates crofelemer's potential for managing symptoms and electrolyte balance in MVID patients. This research supports Napo Therapeutics' application for Orphan Drug Designation from the European Medicines Agency. Crofelemer holds ODD for short bowel syndrome in both the EU and US.

Jaguar Health launched Take C.H.A.R.G.E., a national registry addressing canine cancer, which coincides with National Canine Cancer Awareness Day on May 23, 2022. Initial data from a Gallup Poll of over 3,500 dog owners reveal a 2.8% incidence of canine cancer—five times greater than humans. Over 80% of respondents advocate for a registry to better understand the disease. The registry aims to gather data from 35,000 canine medical records to enhance diagnosis and treatment, highlighting the need for improved canine healthcare.

Jaguar Health is hosting a media event in NYC on May 23, 2022, to launch the Canine Cancer: Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This registry will assess cancer prevalence in dogs by analyzing anonymized medical records and survey data. The event coincides with the inaugural National Canine Cancer Awareness Day and features veterinary cancer specialists and Broadway performances. The initiative aims to improve understanding of canine cancer, benefiting both pets and potentially human health.

Jaguar Health, Inc. (NASDAQ:JAGX) is hosting an event on May 23, 2022, in New York City to launch the Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This initiative aims to assess the impact of cancer on dogs using data from a Gallup survey and thousands of anonymized medical records. The event will feature presentations by veterinary experts and performances by Broadway stars, emphasizing the importance of canine cancer awareness. This launch coincides with the first annual National Canine Cancer Awareness Day.

Jaguar Health (NASDAQ:JAGX) announced an analyst report issued by TAG Investment Bankers, led by analyst Chris Wickham. This report, reflecting paid research, showcases Jaguar Health's capability in the biotechnology sector. The company, focused on developing plant-based medicines for gastrointestinal issues, holds a majority stake in Napo Therapeutics, an entity working to expand crofelemer access in Europe. The ongoing OnTarget study evaluates crofelemer for adult cancer patients to prevent diarrhea. Jaguar maintains a commitment to sustainable harvesting and developing innovative pharmaceutical solutions.

Jaguar Health (NASDAQ:JAGX) launched a telehealth program for its FDA-approved antidiarrheal drug Mytesi on May 6, 2022. This program aims to enhance patient access, especially for those suffering from HIV-related diarrhea. Patients can connect with healthcare providers using mobile devices at their convenience, eliminating long wait times for consultations. The telehealth service underscores the importance of immediate care in addressing sensitive health issues. Mytesi is intended for adults with noninfectious diarrhea related to HIV/AIDS receiving antiretroviral therapy.